This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Britten, C. D. Search for Related Content PubMed PubMed Citation Articles by Britten, C. D.

Minireview

Targeting ErbB receptor signaling: A pan-ErbB approach to cancer

Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California

Requests for reprints: Carolyn D. Britten, Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at University of California at Los Angeles, 10945 Le Conte Avenue, Suite 3360, Los Angeles, CA 90095. Phone: 310-825-8195; Fax: 310-794-5517. E-mail: cbritten{at}mednet.ucla.edu

The ErbB receptors are localized to the cell membrane where they are activated by ligand to trigger a network of signaling pathways. In some cancer cells, dysregulation of ErbB-mediated signaling confers a growth advantage, resulting in cellular transformation and increased metastatic potential. Several agents that inhibit individual ErbB receptors have recently been approved for the treatment of human malignancies, validating ErbB receptors as therapeutic targets. One strategy to improve the efficacy of ErbB-targeted therapies is to inhibit multiple ErbB receptors, thereby interfering with the cooperation that exists between receptors. This minireview addresses the approaches being developed to concurrently inhibit multiple ErbB receptors.

This article has been cited by other articles:

				A E Wakeling Inhibitors of growth factor signalling Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S183 - S187. [Abstract] [Full Text] [PDF]

				M. D. Pegram Molecular Determinants of Trastuzumab Response/Resistance Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 155 - 159. [Full Text] [PDF]

				M. D. Pegram, R. Pietras, A. Bajamonde, P. Klein, and G. Fyfe Targeted Therapy: Wave of the Future J. Clin. Oncol., March 10, 2005; 23(8): 1776 - 1781. [Full Text] [PDF]

				H. Shigematsu, T. Takahashi, M. Nomura, K. Majmudar, M. Suzuki, H. Lee, I. I. Wistuba, K. M. Fong, S. Toyooka, N. Shimizu, et al. Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas Cancer Res., March 1, 2005; 65(5): 1642 - 1646. [Abstract] [Full Text] [PDF]